Research Tissue Bank

NCT ID: NCT00666549

Last Updated: 2019-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

963 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-09-30

Study Completion Date

2017-03-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues:

* Peripheral blood
* Bone marrow
* Bone marrow biopsy
* A phlebotomized unit of blood
* Spleen cells
* Toenail clippings

This material will be used for the study of Myeloproliferative Disorders (MPD) by researchers. The goals of this research study are to understand the causes of MPDs, how to diagnose them more easily and how to treat them better. MPD is a disease affecting hematopoietic stem cells. Hematopoietic stem cells are cells that make blood cells. These stem cells grow in the center portion of the bones called bone marrow. Under some conditions, these cells are also found in blood. There are several diseases, which are classified as MPD. These include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelofibrosis Idiopathic Myelofibrosis Essential Thrombocythemia Polycythemia Vera

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) are eligible.
* Newly diagnose MPD patients as well as previously treated for a MPD are eligible.
* Signed informed consent is required from each patient at the time of enrollment.

Exclusion Criteria

* Patients currently participating in experimental treatment arms of MPD-RC protocols, or other experimental treatment protocols are not eligible during the period they are on study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Myeloproliferative Disorders-Research Consortium

NETWORK

Sponsor Role collaborator

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rona S Weinberg, PhD

Role: STUDY_CHAIR

Myeloproliferative Disorders-Research Consortium

Lewis Silverman, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Palo Alto Medical Foundation Research Institute

Palo Alto, California, United States

Site Status

Weill Cornell University

Washington D.C., District of Columbia, United States

Site Status

University of Georgetown

Washington D.C., District of Columbia, United States

Site Status

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

Johns Hopkins

Baltimore, Maryland, United States

Site Status

Roswell Park

Buffalo, New York, United States

Site Status

Mount Sinai Medical Center

New York, New York, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

Ospedali Riuniti di Bergamo

Bergamo, IL, Italy

Site Status

University of Florence

Florence, IL, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P01CA108671-01A2

Identifier Type: NIH

Identifier Source: secondary_id

View Link

MPD-RC 106

Identifier Type: OTHER

Identifier Source: secondary_id

GCO 07-0548-00106

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thoracic Specimen Registry
NCT04118660 RECRUITING
Biology Studies of Hematologic Cancers
NCT00923442 ENROLLING_BY_INVITATION